New treatment for diabetic peripheral neuropathy using acetylcholine iontophoresis
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
NA · South Valley University · NCT06219590
This study is testing if a new non-invasive treatment using acetylcholine iontophoresis can help improve nerve function in people with type 2 diabetes and peripheral neuropathy.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 40 Years to 60 Years |
| Sex | All |
| Sponsor | South Valley University (other) |
| Locations | 1 site (Qinā) |
| Trial ID | NCT06219590 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of acetylcholine iontophoresis on patients with type 2 diabetes mellitus who have developed peripheral neuropathy. It aims to assess the impact of this treatment on endothelial nitric oxide synthetase and microvascular blood flow. Eighty patients will be randomly assigned to either a treatment group receiving acetylcholine iontophoresis or a control group receiving sham treatment, with follow-up evaluations after a month of aerobic exercise. The goal is to explore a non-invasive therapy that could improve nerve function without systemic side effects.
Who should consider this trial
Good fit: Ideal candidates are adults aged 40-60 with type 2 diabetes mellitus and clinically proven peripheral neuropathy.
Not a fit: Patients with implanted cardiac pacemakers, known skin allergies, skin inflammations, or peripheral vascular disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new, effective, and non-invasive option for managing diabetic peripheral neuropathy.
How similar studies have performed: While this approach is novel, previous studies have explored similar non-invasive treatments for diabetic neuropathy with varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients have to be symptomatically stable with type 2 diabetes mellitus complicated with peripheral neuropathy. * Optimized pharmacological treatment that will be remained unchanged throughout the study. Exclusion Criteria: * Implanted cardiac pacemakers. * Patients with known skin allergies. * Presence of skin inflammations. * Peripheral vascular disease.
Where this trial is running
Qinā
- Faculty of Physical Therapy, South Valley University — Qinā, Egypt (RECRUITING)
Study contacts
- Study coordinator: Reham Ellisy, Dr
- Email: rehamabdelrazekr@gmail.com
- Phone: 01122747361
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Type 2 Diabetes Mellitus, Peripheral Neuropathy, Acetylcholine iontophoresis, diabetic neuropathy, electrophysiological investigations, Nitric oxide, type2 diabetes mellitus, aerobic exercises